

[CLAIMS]

1. Use of a peptide selected from the following in manufacture of a medicament or a reagent for mobilizing mesenchymal stem cells into peripheral blood:
 - 5 (a) a peptide consisting of a portion of the amino acid sequence of SEQ ID NO: 1, and comprising the amino acid sequence of SEQ ID NO: 17 or 19;
 - (b) a peptide consisting of all or a portion of an amino acid sequence resulting from substitution, deletion, insertion, or addition of one to five amino acids in the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID
10 NO: 17 or 19; and
 - (c) a peptide consisting of all or a portion of an amino acid sequence having a sequence identity of 90% or higher with the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19.
- 15 2. Use of a peptide selected from the following in manufacture of a medicament for treating a disease or pathological condition in a subject by mobilizing mesenchymal stem cells into peripheral blood:
 - (a) a peptide consisting of a portion of the amino acid sequence of SEQ ID NO: 1, and comprising the amino acid sequence of SEQ ID NO: 17 or 19;
 - 20 (b) a peptide consisting of all or a portion of an amino acid sequence resulting from substitution, deletion, insertion, or addition of one to five amino acids in the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19; and
 - (c) a peptide consisting of all or a portion of an amino acid sequence having a sequence
25 identity of 90% or higher with the amino acid sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO: 17 or 19.
3. The use of claim 2, wherein the treatment of a disease or pathological condition is selected from inflammation-suppressing therapy, immunomodulatory therapy, tissue regeneration-
30 inducing therapy, and tissue fibrosis-suppressing therapy.
4. The use of claim 2, wherein the disease or pathological condition is selected from an inflammatory disease, an autoimmune disease, a disease accompanied by tissue damage, ischemia, or necrosis, and a fibrotic disease.
35
5. The use of claim 2, wherein the disease or pathological condition is inflammatory bowel

disease.

6. The use of claim 2, wherein the disease or pathological condition is ulcerative colitis.

5 7. The use of claim 2, wherein the disease or pathological condition is atopic dermatitis.

8. The use of claim 2, wherein the disease or pathological condition is cerebral infarction.

9. Use of a peptide selected from the following in manufacture of a medicament for treating a
10 disease selected from inflammatory bowel disease, atopic dermatitis, and cerebral infarction:

(a) a peptide consisting of a portion of the amino acid sequence of SEQ ID NO: 1, and
comprising the amino acid sequence of SEQ ID NO: 17 or 19;

(b) a peptide consisting of all or a portion of an amino acid sequence resulting from
substitution, deletion, insertion, or addition of one to five amino acids in the amino acid
15 sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID
NO: 17 or 19; and

(c) a peptide consisting of all or a portion of an amino acid sequence having a sequence
identity of 90% or higher with the amino acid sequence of SEQ ID NO: 1, wherein the peptide
comprises the amino acid sequence of SEQ ID NO: 17 or 19.

20

10. A peptide selected from the following:

(a) a peptide consisting of a portion of the amino acid sequence of SEQ ID NO: 1, and
comprising the amino acid sequence of SEQ ID NO: 17 or 19;

(b) a peptide consisting of all or a portion of an amino acid sequence resulting from
25 substitution, deletion, insertion, or addition of one to five amino acids in the amino acid
sequence of SEQ ID NO: 1, wherein the peptide comprises the amino acid sequence of SEQ ID
NO: 17 or 19; and

(c) a peptide consisting of all or a portion of an amino acid sequence having a sequence
identity of 90% or higher with the amino acid sequence of SEQ ID NO: 1, wherein the peptide
30 comprises the amino acid sequence of SEQ ID NO: 17 or 19.